FindMyKOL
Clinical trialNCT03371082CompletedPhase 3Interventional

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082 is a phase 3 interventional trial sponsored by Gan and Lee Pharmaceuticals, USA. As of 21 Nov 2026, it is completed. It studies Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 1. The registry lists an enrollment of 576 participants at 85 sites in 6 countries. The registry lists a start date of 31 Oct 2017 and a primary completion date of 19 Aug 2019.

SponsorGan and Lee Pharmaceuticals, USAEnrollment576Diabetes Mellitus, Type 1
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03371082
FieldValue
Registry IDNCT03371082
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorGan and Lee Pharmaceuticals, USA
Enrollment576
Registered sites85
Countries6
ConditionsDiabetes Mellitus, Type 1
DrugsGan & Lee Insulin Glargine Injection and Lantus®
Start31 Oct 2017
Primary completion19 Aug 2019
Study completion19 Aug 2019
Last update posted14 May 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: • To evaluate the percentage of subjects with negative anti-insulin antibodies (AIAs) at baseline who develop confirmed positive AIA up to Week 26, the percentage of baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and percentage of subjects who develop confirmed positive AIA up to visit Week 26 of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®. Safety: •To evaluate the safety of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®. Efficacy: •To evaluate the efficacy of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

85 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States1 site
  • University of Alabama at Birmingham

    Birmingham

California, United States4 sites
  • Valley Research

    Fresno

  • the Rose Salter Medical Research Foundation

    Newport Beach

  • California Medical Research Association

    Northridge

  • Metabolic Institute of America

    Tarzana

Connecticut, United States1 site
  • Cmr of Greater New Haven, Llc

    Hamden

Florida, United States11 sites
  • Meridien Research

    Bradenton

  • the Center for Diabetes and Endocrine Care

    Fort Lauderdale

  • Homestead Associates in Research

    Homestead

  • Central Florida Endocrine and Diabetes Consultants - Maitland

    Maitland

  • Biotech Pharmaceutical Group, Llc

    Miami

  • Miami Dade Medical Research Institute, Llc

    Miami

  • New Horizon Research Center

    Miami

  • Suncoast Clinical Research, Inc.

    New Port Richey

  • Peninsula Research

    Ormond Beach

  • Oviedo Medical Research, Llc

    Oviedo

  • Metabolic Research Institute, Inc.

    West Palm Beach

Georgia, United States4 sites
  • River Birch Research Alliance, Llc

    Blue Ridge

  • Iresearch Atlanta

    Decatur

  • Sestron Clinical Research

    Marietta

  • Endocrine Research Solutions, Inc.

    Roswell

Hawaii, United States1 site
  • East-West Medical Research Institute

    Honolulu

Idaho, United States1 site
  • Advanced Clinical Research - Idaho

    Meridian

Illinois, United States3 sites
  • Cedar Crosse Research Center

    Chicago

  • John H. Stroger Jr. Hospital of Cook County

    Chicago

  • Midwest Crc

    Crystal Lake

Iowa, United States1 site
  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines

Kentucky, United States1 site
  • Kentucky Diabetes Endocrinology Center

    Lexington

Nevada, United States1 site
  • Palm Research Center, Inc.

    Las Vegas

North Carolina, United States1 site
  • Physicians East - Greenville

    Greenville

North Dakota, United States1 site
  • Lillestol Research Llc

    Fargo

Ohio, United States3 sites
  • Aventiv Research, Inc.

    Columbus

  • Endocrinology Reserach Associates, Inc.

    Columbus

  • Primed Clinical Research

    Dayton

Tennessee, United States3 sites
  • Clinsearch - Clinical Research Specialists

    Chattanooga

  • University Diabetes & Endocrine Consultants

    Chattanooga

  • New Phase Research & Development

    Knoxville

Texas, United States6 sites
  • Texas Diabetes & Endocrinology - Central Austin

    Austin

  • Texas Diabetes & Endocrinology - South Austin

    Austin

  • Research Institute of Dallas

    Dallas

  • Texas Diabetes & Endocrinology - Round Rock

    Round Rock

  • Clinical Trials of Texas

    San Antonio

  • Northeast Clinical Research of San Antonio

    Schertz

Utah, United States3 sites
  • Radiant Research

    Murray

  • Advanced Research Institute

    Ogden

  • Wasatch Clinical Research, Llc

    Salt Lake City

Virginia, United States1 site
  • Burke Internal Medicine & Research

    Burke

Washington, United States3 sites
  • Stonesifer Clinical Research

    Federal Way

  • Rainier Clinical Research Center, Inc.

    Renton

  • Multicare Health System Institute for Research & Innovation

    Tacoma

Spain8 sites
  • Hospital Universitari de Girona Doctor Josep Trueta

    Girona, Gerona

  • Complejo Hospitalario Universitario de Ferrol

    Ferrol, LA Coruna

  • Centro de Especialidades San Jose Obrero. Hospital Universitario Virgen de la Victoria

    Málaga, Malaga

  • Complejo Hospitalario Universitario la Coruña

    A Coruña

  • Hospital Universitario Ramón Y Cajal

    Madrid

  • Hospital Universitario Nuestra Señora de Valme

    Seville

  • Nuevas Tecnologías En Diabetes Y Endocrinología

    Seville

  • Consorci Hospital General Universitari de València

    Valencia

Czechia7 sites
  • Krajská Zdravotní, A.S., Masarykova Nemocnice V Ústí Nad Labem

    Ústí nad Labem, Severoceský KRAJ

  • Diabetologie České Budějovice S.R.O

    České Budějovice, South Bohemian Region

  • Diahaza S.R.O.

    Holešov

  • Stefamed

    Hradec Králové

  • Diabetologie Mudr. Tomáš Edelsberger

    Krnov

  • Preventamed

    Olomouc

  • Genom S.R.O

    Ostrava

Hungary7 sites
  • Cru Hungary Egészségügyi És Szolgáltató Kft.

    Miskolc, Borsod-Abauj Zemplen county

  • Lausmed Egeszsegugyi Es Szolgaltato Kft.

    Baja, Bács-Kiskun county

  • Markhot Ferenc Oktatókórház És Rendelointézet

    Eger, Heves County

  • Zala County Hospital

    Zalaegerszeg, Zala County

  • Betegapolo-Irgalmasrend Budai Irgalmasrendi Kórház, Diabetológiai Ambulancia

    Budapest

  • Semmelweis Egyetem Ii. Sz. Belgyógyászati Klinika

    Budapest

  • Synexus Magyarország

    Budapest

Poland7 sites
  • Praktyka Lekarska Ewa Krzyzagórska

    Poznan, Greater Poland Voivodeship

  • Nzoz Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne "diab-Endo-Met"

    Krakow, Lesser Poland Voivodeship

  • Pratia Mcm Kraków

    Krakow, Lesser Poland Voivodeship

  • Ko-Med Centra Kliniczne Lublin - Królewska

    Lublin, Lublin Voivodeship

  • Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji W Warszawie

    Warsaw, Masovian Voivodeship

  • Centrum Badań Klinicznych Pi-House

    Gdansk, Pomeranian Voivodeship

  • Niepubliczny Zaklad Opieki Zdrowotnej Gdanska Poradnia Cukrzycowa

    Gdansk, Pomeranian Voivodeship

Germany6 sites
  • Studienzentrum Aschaffenburg

    Aschaffenburg, Bavaria

  • Diabetes-Falkensee.de

    Falkensee, Brandenburg

  • Gemeinschaftspraxis Diabeteszentrum Dortmund

    Dortmund, North Rhine-Westphalia

  • Diabetes Schwerpunktpraxis, Gemeinschaftspraxis Alain Barakat Und Helene Willems

    Duisburg, North Rhine-Westphalia

  • Diabetologische Schwerpunktpraxis Pirna

    Pirna, Saxony

  • Red-Institut Gmbh

    Oldenburg in Holstein, Schleswig-Holstein

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 3 sitesWA3MontanaMTNorth Dakota: 1 siteND1MinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdaho: 1 siteID1South DakotaSDIowa: 1 siteIA1Illinois: 3 sitesIL3IndianaINOhio: 3 sitesOH3PennsylvaniaPANew JerseyNJConnecticut: 1 siteCT1California: 4 sitesCA4Nevada: 1 siteNV1WyomingWYNebraskaNEMissouriMOKentucky: 1 siteKY1West VirginiaWVVirginia: 1 siteVA1MarylandMDDelawareDEArizonaAZUtah: 3 sitesUT3ColoradoCOKansasKSArkansasARTennessee: 3 sitesTN3North Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabama: 1 siteAL1Georgia: 4 sitesGA4Hawaii: 1 siteHI1Texas: 6 sitesTX6Florida: 11 sitesFL11District of ColumbiaDC
Fewer sitesMore sites

Outside the United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gan & Lee Insulin Glargine InjectionLantus®
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03371082

Each answer restates registry values shown on this page.

What is NCT03371082?

NCT03371082 is a phase 3 interventional trial sponsored by Gan and Lee Pharmaceuticals, USA. It studies Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 1.

Who leads NCT03371082?

The registry names Elena A. Christofides, MD,FACE (principal investigator, Endocrinology Research Associates, Inc.) and Jia Lu, MD, PhD (study director, Gan & Lee Pharmaceuticals, USA) as overall officials.

Where does NCT03371082 run?

The registry lists 85 sites in 6 countries. Most sites are in these countries: United States (50), Spain (8) and Czechia (7).

Which drugs does NCT03371082 study?

The registered drug and biological interventions are Gan & Lee Insulin Glargine Injection and Lantus®.

When did NCT03371082 end?

The registry lists a primary completion date of 19 Aug 2019 and a study completion date of 19 Aug 2019. The sponsor last updated the record on 14 May 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.